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Summary 
The leukocyte integrin LFA-1 (CD1 la/CD 18) plays an important role in lymphocyte recircu- 
lation and homotypic interactions. Leukocytes from mice lacking CD11a displayed defects in 
in vitro homotypic aggregation, in proliferation in mixed lymphocyte reactions, and in response 
to mitogen. Mutant mice mounted normal cytotoxic T  cell (CTL) responses  against systemic 
LCMV and VSV infections and showed normal ex vivo CTL function. However, LFA-l-defi- 
cient mice did not reject immunogenic tumors grafted into footpads and did not demonstrate 
priming response against tumor-specific antigen. Thus CD11a deficiency causes a selective de- 
fect in induction of peripheral immune responses  whereas responses  to systemic infection are 
normal. 
T 
he  CD11a/CD18  (LFA-1)  complex,  a  cell  adhesion 
molecule  essential  for  cell-mediated cytotoxicity by 
T-lymphocytes (CTL) and natural killer (NK) cells, plays an 
important role in host defense (1,  2).  The natural ligands 
for LFA-1 are ICAM-1, ICAM-2, and ICAM-3, which have 
been shown to facilitate interactions between T  lympho- 
cytes and endothehal tissues, target cells (3, 4), and antigen- 
presenting cells  (APC)  (5,  6).  LFA-1 belongs to the [32- 
integrin  family of adhesion  molecules,  whose  members 
include MAC-1 (CD11b/CD18), p150,95 (CD11c/CD18), 
and  a  putative  heterodimer  recently  described  (7). The 
CDt lb/CD18 heterodimer has been found to be important 
for non-specific adhesion of granulocytes and monocytes to 
endothelial cells, and CD11c/CD18  is reportedly a phago- 
cyte receptor involved in activating cells after binding to bac- 
terial LPS in infected tissues  (8). LFA-1  is thought to be 
more involved in lymphocyte function (9) and is expressed 
on lymphocytes, monocytes, granulocytes, and bone mar- 
row cells. A hereditary mutation in the [3-chain (CD18) of the 
[32-integrin  family results in a reduction or lack of a func- 
tional CD11a/CD18 (LFA-1), CD11b/CD18,  and CD11c/ 
CD18 heterodimers. Children affected by this lymphocyte 
adhesion deficiency (LAD) suffer from extreme susceptibil- 
ity to bacterial and fungal infections (10-13). 
Whereas a genetic defect in the CD18 gene results in the 
obliteration  of all  three  [3-2 integrins,  CDlla-deficient 
mice were expected to lack only the LFA-1 family mem- 
ber. Lymphocytes have been shown to require the LFA-1 
heterodimer for normal inflammatory responses  in vivo (3, 
14). Early studies  suggested that LFA-1 probably was cru- 
cial to early phase induction of immune responses  but was 
not as important for lymphocyte prohferation (1, 15). Other 
results have implicated LFA-1 in recirculation and effector 
function of primed T lymphocytes. Simultaneous injection 
of  anti-LFA-1  mAb  with  2,4  dinitro-fluorobenzene 
(DNFB) 1 rechallenge blocked DTH  responses  in DNFB- 
primed mice, which accompanied a significant reduction in 
the  number  of  lymphocytes  in  lymph  nodes  draining 
treated skin (16). In addition, adoptive transfer of LCMV 
primed lymphocytes treated with anti-LFA-1 mAb blocked 
the development of DTH responses  in naive recipient ani- 
mals (17). 
Early studies  with T-cell lines indicated a possible  func- 
tional role for LFA-1 in CTL killing of  target cells (1, 18, 19). 
More recent reports have indicated that tumor-specific CTL 
against lymphoma cells require LFA-1 expression for normal 
killing responses  (20),  and that virus-induced tumor pro- 
gression is  enhanced in anti-LFA-1  treated mice,  report- 
IAbbreviations used in this paper: DNFB, 2,4 dinitro-fluorobenzene;  DTH, 
delayed-type  hypersensitivity;  ES, embryonic  stem cells; LCMV, lympho- 
cyte choriomeningitis  virus; VSV, vesicular  stomatitis  virus. 
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but, rather, as a result of impaired CTL killer function (21). 
The role of LFA-1  in recirculation has  been supported 
by in vitro  and in vivo studies.  Monoclonal antibody to 
LFA-1 inhibits in vitro adherence oflymphocytes to lymph 
node HEV prepared from frozen sections and significantly 
reduces  migration of lymphocytes into lymph nodes  and 
Peyer's patches (22).  The presence or absence of ICAM-1 
on HEV has no modulatory effect on lymphocyte attach- 
ment and rolling at HEV (4). Lymphocytes expressing high 
levels of MEL-14 are  also less  suceptible to  the  effects  of 
anti-LFA-1 antibody blocking effects on lymphocyte adhe- 
sion to HEV (22). This data on the role of LFA-1 in T  cell 
recirculation raises questions as to the role of the molecule 
during normal homing responses in vivo. 
Splenocytes deficient for ICAM-1 are almost totally de- 
fective  as  stimulators in an MLR  (6).  Antibody-blocking 
studies against ICAMs 1, 2, or 3 showed that dendritic cell 
APC  function for T  cells was  abrogated by mAbs against 
ICAM-1  or  2  but not by mAb directed  at  ICAM-3  (5). 
Both  induction and  expansion of lymphocytes  has  been 
shown to  require LFA-1. Anti-LFA-1 mAb block T  cell 
induction phase to alloantigen but have no effect on prolif- 
eration  during bulk  expansion  of alloresponding T  cells 
(23).  These  studies  and others  have  revealed that  the  re- 
quirement of LFA-1 by T  cells for proliferative responses to 
antigen can vary depending on the type of APC (24).  Clar- 
ification is  needed on the role of LFA-1  in the induction 
antigen-specific CTL. 
We have disrupted the  murine CDlla  gene in embry- 
onic stem cells (ES) cells and generated a mouse strain pos- 
sessing targeted disruption of both alleles of the CD1 la gene. 
We observed reduced proliferative responses of enriched T 
cells in in vitro MLR and after mitogenic stimulation. Un- 
expectedly, CD 1 la homozygous mutant mice mounted nor- 
mal T  cell responses to lymphocyte choriomeningitis virus 
(LCMV) and vesicular stomatitis virus (VSV)  infections and 
exhibited normal ex vivo CTL function. However, mutant 
mice  showed  defective  peripheral priming against  tumor 
cells  expressing a  tumor-specific antigen and  in  addition 
were unable to clear tumors injected into footpads. 
Materials and Methods 
Preparation of Targeting Construct.  To prepare  a gene targeting 
construct, a murine 129 genomic DNA library (Stratagene  Inc., 
La Jolla,  CA) was screened using oligonucleotides corresponding 
to  the  5'  end of the  murine CDlla cDNA.  A  single  lamb& 
clone containing exons 1 to 6 was isolated. A construct for ho- 
mologous recombination was prepared by ligation ofa KpnI/SalI 
fragment  (containing the  pMClneo polyA neomcin resistance 
casette) with a 5-kb 5' XbaI/KpnI fragment and a 0.6-kb 3' SalI/ 
Xbal fragment corresponding to the murine CD11a gene. The 
long arm of this construct contains exon 1 and part of intron 1, 
and the short  arm contains the 3' portion of exon 6 and part of 
intron 6.  The targeting construct replaces exons 2, 3,  4,  5,  and 
part of exon 6 with the neomycin resistance casette. The first six 
exons  correspond to the signal peptide and the amino-terminal 
extracellular  region  of the  CD11a  gene.  A  500-bp  HindllI/ 
BamHI restriction fragment immediately upstream of the region 
included in the mCD1 la targeting construct was used as a probe 
in Southern blot analysis for targeted  events. 
Generation Of ES Cell Line and Mice.  The ES cell line E14 K was 
electroporated  with the CD 1  l a construct, which was linearized at 
the unique NotI site in the BluescriptlI polylinker at the 3' end. 
Individual  colonies were picked after 10 d of selection in 500 I.tg/ 
ml of G418 and analyzed by PCR using a primer contained within 
the  neo casette  (5'  AAC  GCA CGG  GTG TTG GGT CGT 
TTG 3')  paired  with  an outside  primer (5'  ACC  AGT CTC 
TGC TTC TTC TGC AC 3')  located in the  murine CD11a 
gene 3'  to the targeting construct. Positive  clones  identified by 
PCR were  confirmed using Southern blotting and hybridizing 
with a flanking probe. 
Targeted ES cell clones were injected into day 3.5 C57 BL/6J 
blastocysts and transferred into the uteri of CD 1 pseudo-pregnant 
foster  mothers,  as previously described  (25-27).  Chimeric male 
and female  offsprings were bred to  C57  BL/6J,  and germ-line 
transmission  of the mutation was documented by PCR and by 
Southern blotting of tail DNA digested with EcoRI and hybrid- 
ized with the 5' flanking probe. Mice demonstrating germ line 
transmission  of the targeted  allele were then bred to obtain ho- 
mozygous gene  targeted  offspring  and further backcrosses  into 
C57 BL/6J. 
Analysis of Circulating Leukocyte Counts in the Gene-targeted Mice. 
Peripheral  blood of anesthetized  mice was collected from the ret- 
roauricular plexus  in EDTA-capillary tubes  or by cardiac punc- 
ture at the time of death. Whole blood was diluted 1:3 in Hanks 
BBS and total white blood cell counts determined on a hemocy- 
tometer.  The absolute numbers of each leukocyte population were 
calculated by multiplying total white blood cell counts by differ- 
entials. Blood smears were prepared and stained  with Leukostat 
(Sigma Chem. Co., St. Louis, MO) to count differentials. 
Flow Cytometry of Gene-targeted Mice.  Cell suspensions fi'om thy- 
mus,  spleen,  lymph nodes,  and bone marrow  of 6-12-wk-old 
mice  were  prepared  free  from  red  blood  cells. For  two-  and 
three-color flow cytometry, 5 ￿  10  s cells in 100 p,1 were stained 
with  antibodies  directly  conjugated  with  FITC  or  PE:  anti- 
CD11a (clone M17/4; PharMingen, San Diego, CA), anti-CD4 
(clone  YTS  191.1.2;  Cedarlane Labs. Ltd.,  Hornby, ON),  anti- 
CD8  (clone  YTS  169.4;  Cedarlane  Labs.), anti  CD18  (clone 
C71/16), anti CDllb/Mac-1 (clone M1/70), anti-CD3 (clone145 
2Cll), anti-B220 (clone  RA3-6B2), or anti-GR1 (clone  R.B6- 
8C5; all PharMingen). Cells were incubated at 4~  for 30 min, 
washed  three times,  and fixed in PBS/1% paraformaldehyde  be- 
fore  analysis on  a  FACScan  |  instrument  (Becton-Dickinson, 
Mountain View, CA). FACS  |  analysis  was performed with Lysis II 
(Becton-Dickinson).  Windows for  analysis of granulocytes  and 
lymphocytes were set using side scatter and forward scatter. 
Contact Hypersensitivity.  Contact hypersensitivity was elicited 
in mice by using DNFB. In brief, 6-8-wk-old mice were immu- 
nized on the shaved abdomen with 50 p~l 0.5% DNFB in 4:1 ace- 
tone/olive oil at day 0 and day 1. At day 5 these mice were chal- 
lenged with 10 }xl 0.2% DNFB in 4:1  acetone/olive oil on the 
inner and outer side of one ear. Ear thickness was measured  24 h 
after reexposition and compared with the untreated ear. 
Thioglycollate-induced Peritonitis.  Aged and sex-matched mice 
were injected i.p.  with 1.5 ml 4% thioglycollate  on d 0. At +4, 
+24, and +72 h mice were injected i.p. with 8 ml of PBS (with- 
out Ca ++  and Mg  ++,  2 mM EDTA, 50  b~m/rnl heparin),  their 
abdomens were massaged and 7 ml oflavage fluid was withdrawn. 
Peritoneal lavage  cells were  washed  3￿  in PBS  without Ca ++ 
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counts were performed after staining with Turk's solution. 
In Vitro Proliferation Assay.  Lymph node (LN) cells from +/+, 
+/-  and  -/-  mice were harvested and  105  cells were stimu- 
lated hamster anti mouse CD3 mAb (clone 145 2C11; PharMin- 
gen) (10 ~g/ml) in HL-1 media (Hycor Biomedical, Irvine, CA) 
containing 2%  FCS  using  96  well round  bottom plates.  Cells 
were pulsed overnight with [3H]thymidine after 24, 48, or 72 h. 
For cross-linking antibody stimulation 96-well flat bottom plates 
were  used  and preincubated with  rabbit anti-hamster IgG the 
night before. Cells were pulsed overnight with [3H]thymidine af- 
ter 48 h. Proliferation was measured by [3H]thymidine incorpora- 
tion using Matrix 96-Beta-counter. 
Mixed Lymphocyte Reaction (MLR).  MLR's were performed by 
mixing spleen cells from C57BL/6J,  bin12, BALB/c or B10.BR 
animals with responder cells from LN cells  or enriched T-cells 
from LNs and spleen of wild-type or mutant hybrid (129Sv  ￿ 
C57BL/6J)  animals. Stimulator spleen cells were irradiated with 
20001:(, washed twice and 1 ￿  10  s cells were cocultured with 1 ￿ 
105  responder  lymph  node  cells  or  column  enriched  T  cells 
(R&D Systems, Inc., Minnneapolis, MN). Assays were performed 
in quadruplicate in 96-well flat-bottom Microtiter plates in HL-1 
media (Hycor Biomedical) containing 2% heat inactivated FCS. 
Cells were pulsed at day 4 with 1 mCi ([3H]thymidine) for 16 h 
and proliferation measured by [3H]thymidine incorporation using 
Matrix 96-Beta counter (Camberra Packard). 
Natural Killer Cell Function.  For induction of NK activity in 
vivo, mice  were  injected intraperitoneally with  either  100  Ixg 
poly(I):poly(C) or saline on days 0 and 1. On clay 2 mononuclear 
spleen cells were isolated by density gradient centrifugation over 
lympholite M  and resuspended at 4  ￿  106 cells per nil in com- 
plete media. Mononuclear cells obtained after in vivo induction 
of NK activity were coincubated with SlCr-labeled YAC-1 target 
cells (gift from  R.  Miller,  Ontario  Cancer  Institute,  Toronto, 
Ontario). Percent specific lysis is given as: % Sp.Lys.  =  (experi- 
mental counts -  spontaneous counts)/(total counts -  spontane- 
ous counts). 
HomotypicAggregation of Splenocytes.  Spleen suspension from +/- 
and  -/-  mice were prepared according to standard procedures 
by straining spleens through wire mesh. Cells were washed twice 
and resuspended in DMEM, 5% FCS, Glutamine (200 mM) and 
b2-ME (10 -6 M). Then 103-105 cells per well (1 ml) were added 
to 24-well plates. Cells were incubated for 24 h in the presence of 
100 ng/m_l PMA. Cell were observed using light microscopy and 
aggregation was determAned as either present or absent. 
Viruses.  VSV grown  in BHK  cells  was  kindly provided by 
Dr. Lud Prevec (McMaster University, Hamilton, Ontario, Can- 
ada).  LCMV (Armstrong isolate) grown in BHK cells was origi- 
nally obtained from  Dr.  M.B.A.  Oldstone  (Scripps Clinic and 
Research Foundation, LaJolla, CA) (28). 
Primary Ex Vivo CTL Assay Using Cell Ia'ne Targets.  Mice  were 
infected with VSV (2 ￿  106 pfu i.v.) or with LCMV (2 ￿  103 pfu 
i.v.) and spleens were removed after 6 or 8 d, respectively. Spleen 
cells were coincubated for 5  h  with SlCr-labeled MC57  (H-2  b) 
and/or EL-4 (H-2  b) target cells, which were infected with VSV 
or loaded with  LCMV-GP  peptide  (aa33-41,  50  raM,  2  h  at 
37~  MC57 cells and EL-4 were infected with VSV for 2 h (15 
pfu per cell) before the assay. Specific lysis was calculated as (ex- 
perimental release -  spontaneous release)/(total release -  spon- 
taneous release)  ￿  100%. 
Fan'mary Ex Vivo CTL Assay Using Macrophage Targets.  LCMV- 
specific CTL were derived as above and ex vivo CTL function 
was determined using targets derived from  -/-  mutant  mice. 
Target cells were obtained by injecting mice with 1 ml thiogly- 
collate at day -5  and harvesting macrophages by peritoneal la- 
vage  at  day  -1.  Macrophages  were  seeded  into  flat-bottom 
96-well plates and incubated overnight with  IMDM  10%  FCS 
containing SlCr sodium chromate (0.2 mCi/ml). Cells were then 
pulsed with  10-5  M  LCMV-gp peptide.  After 2  h,  cells were 
washed twice and spleen cells were added. 5 h later, 70 ml were 
pipetted off and radioactivity in the supematant determined in a 
"/-counter. Since cell numbers and S~Cr uptake in individual wells 
varies, total release of SlCr was determined in each well by lysing 
cells with 70 bd of HC1 (1 M) and counting radioactivity remain- 
ing in the well; counts derived from 70 l.tl supernatant plus re- 
maining counts were taken as 100%. 
Assay for Secondary Responses against VSV.  Mice were immu- 
nized i.v. with VSV  (2  ￿  106  p.f.u.,  Indiana strain). After 6  d 
spleen cells were  restimulated with  specific antigen  by  adding 
VSV nuclear protein class-l-binding peptide (50  raM)  to bulk 
cultures as previously described (29).  After 5 d, in vitro culture 
were harvested and tested for specific cytotoxicity against VSV- 
infected EL-4 (H-2  b) target cells.  Specific lysis was calculated as 
above. 
Tumor Rejection.  Heterozygous and homozygous mutant mice 
[129JSv  (H-2  b) ￿  C57BL/6J  (H-2B)] were anesthetized and 2  ￿ 
105 MC57  (H-2  b) fibrosarcoma-cells (generated from C57BL/6J) 
were injected into left hind footpads. Footpad swelling was mon- 
itored daily or every second day and measured using a  spring- 
loaded caliper. Footpad swelling is given in percent as compared 
to uninjected footpad. MC57gp  cells were also injected at 2  ￿ 
10  s  cells  into  the  left-hind footpad of mice  and injected mice 
were monitored in the same way, or screened for CTL induction. 
In  Vitro Restimulation of Cytotoxic T Cell Activity afier lmmuniza- 
tion with Tumor.  MC57-GP  is  a  methylcholantren induced fi- 
brosarcoma  (originating from  C57BL/6  (H-2  b  mice)  that  has 
been transfected to stably express an LCMV glycoprotein, which 
contains  the  immunodominant  epitope  for  CD8+  T  cell  re- 
sponses against LCMV infections (described previously in detail 
[30]).  2 ￿  10 s MC57-GP were injected into the left hind foot- 
pads of mice,  at  day 7  spleens were  removed  and single cell 
suspensions  restimulated  in  vitro  using  irradiated  (2,000  rad) 
LCMV-GP peptide-labeled spleen cells. After 5 d cultures were 
harvested and tested for generation of LCMV-GP-specific CTL 
activity  against  EL-4  target  cells,  which  were  labeled  with 
LCMV-GP peptide (aa33-41, 50 raM,  2 h  at 37~  EL-4 cells 
incubated without peptide were used as controls for specificity. 
Specific lysis was calculated as (experimental release -  spontane- 
ous release)/(total release -  spontaneous release)  ￿  100%. 
Results 
Disruption  of CDI la  Gene and  Generation  of Homozygous 
Mutant Mice.  Successfully targeted ES cells possessed a 9-kb 
fragment  on  Southern  blotting  compared  to  the  13-kb 
wild-type fragment using a probe from the 5' flanking re- 
gion of the CDlla  gene  (Fig.  1,  C  and D). All confirmed 
clones were  analyzed with  the  neo probe  to  ensure  single 
integration  events.  Targeted ES  cell clones  were  injected 
into  C57/BL/6J  blastocysts and male  chimeric mice were 
bred to  C57B1/6J  mice.  Germ line transmission was  con- 
firmed by Southern blotting for two  of the independently 
derived ES cell clones. Southern blotting studies from wild- 
type  (+/+),  heterozygous  (+/-),  and  homozygous  mu- 
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Figure  1.  Generation  of 
CDlla deficient mice.  (A) Re- 
striction  map  of  the  murine 
CDlla. Boxes represent exons 1 
to 6; flanking probe is designated 
*.  (/3) Targeting vector  replaces 
exon 2-5 of the  ICAM binding 
region  (44). (C)  Map  of pre- 
dicted  homologous  recombina- 
tion ofgene targeting vector. (D) 
EcoRl  digestion and hybridiza- 
tion  results in a 9-kb gene tar- 
geted  fragment compared  to  a 
13-kb  wild-type  EcoR1  frag- 
ment.  (E)  Southern blot of ho- 
mozygous wild-type and mutant 
mice. Genotypes are indicated at 
the top of each lane: +/+ wild- 
type;  +/-  heterozygote;  and 
-/-  homozygous mutant. 
tant  (-/-)  mice  were  performed to  document  the  pres- 
ence of mutation. The expected 13-kb wild-type and 9-kb 
targeted  fragments  were  observed  using  the  HindlII/ 
BamHI flanking probe (Fig. 1 E). Additional digestions and 
the use of neo as a probe confirmed the presence of targeted 
allele. Heterozygous and homozygous mutant animals were 
born  in  expected  ratio,  survived and  grew  normally,  and 
were fertile. Animals did not demonstrate any obvious phe- 
notype and remained healthy when maintained under spe- 
cific pathogen-free conditions. 
Splenomegaly and Reduced Lymph Node Size in CD 1 la  -~- 
Mice.  Analysis of 6-wk-old mice  (n  =  6)  did not  reveal 
any gross abnormalities in  tissue architecture  of major or- 
gan  systems.  However,  6-wk-old mutant  mice  had  two- 
fold  enlargement  of spleen, while  lymph  nodes  were  ap- 
proximately one-fourth  normal size, reflecting higher and 
lower  numbers  of  lymphocytes,  respectively  (data  not 
shown). An interesting exception of these observations was 
the  finding that  mesenteric  lymph  nodes  were  of normal 
size and cellularity. 
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spite differences in size and cellularity of spleen and lymph 
nodes in mutant mice, surface markers indicated that lym- 
phocyte  subset  ratios  were  unchanged  in  these  tissues. 
Analysis of lymphocyte subsets and peripheral blood leuko- 
cytes (PBL) confirmed that B220-, CD3-, and CD11b-posi- 
five ceils were negative for CD11a expression (Figs. 2 and 
3). In addition, the cell surface expression of CD18 was re- 
duced to levels expected for its presence only in the MAC-1 
heterodimer (Fig.  3).  Since  thymocyte selection is  influ- 
enced by thymocyte avidity with stromal cells,  which are 
known  to  express  ICAM-1  (31),  the  LFA-1  deficiency 
might  be  expected  to  influence  thymocyte  ontogeny. 
However, thymocyte cell numbers were normal (data  not 
shown), as were CD4-CD8 profiles (Fig. 4). 
Immunoglobulin Levels Are Normal  in  CDI la  -/-  Mice. 
Ig subclass irregularities can reflect general dysfunction of  the 
immune system (32). Moreover, since LFA-1 and ICAM-1 
can be upregulated on T  and B  cells  (3),  it is conceivable 
that CD11a might play a role in T:B cell cooperation and, 
perhaps,  in  Ig  class switching.  We  found  mutant  mice 
housed under pathogen-free conditions to have normal se- 
rum Ig levels (IgM, IgG1, IgG2, IgG2a, IgG2b, IgG3, and 






￿9  ,  [ 
:!,!  :?:  : 
t 
~r 
￿9  .  q  ..~;:. 
￿9  ]  .".. 
+/4- 
..'i~  :~::~-  '  +/- 
4 
"-~  .  ~  .~, ~....-.-:  -r  .  ,.:  ;. 
-  '  ..!.i.,..:..~:.  : 
~" 
--1() 0  101  1()  ~'  1()  3  1~  4  --  4 
B 220  CD 3 
4- 
Figure 2.  B  and T  cells lack surface expression of CDlla.  Peripheral 
blood cells were stained with PE-conjugated anti-CD1 la and FITC-con- 
jugated anti-B220.  Lymph node cells were  stained with PE-conjugated 
anti-CDlla  and  FITC-conjugated  anti-CD3.  Mice  with  homozygous 
disruptions in CD1 la gene show no detectable surface expression. FACS  | 
data was collected for viable lymphocytes according to SSC and FSC. 
1419  Schmits  et al. 
Homotypic Aggregation Is Defective in  CD11a  -/-  Mice. 
Peripheral blood lymphocytes, T  cells, B cells, and myeloid 
lineage cells have been shown to aggregate in response to 
phorbol esters  (33-35), and can be blocked by anti-LFA-1 
mAb (9). Lymphocytes from LAD patients have also been 
found not to aggregate in response to phorbol-ester activa- 
tion (34).  To assess leukocyte adhesion in vitro, we incu- 
bated spleen cells with PMA for 24 h  and monitored for 
aggregation (33,  36).  Leukocytes from heterozygous mice 
formed aggregates, indicative ofhomotypic adhesion, whereas 
leukocytes  from  mutant  mice  failed  to  aggregate  in  re- 
sponse to PMA (Fig. 5 A). 
CD11a  -/-  Enriched T  Cells Show  Reduced  Prolifera- 
tion.  Anti-LFA-1 antibody can inhibit T  cell proliferative 
responses  to  soluble  antigens,  alloantigens  and  mitogens 
(23, 24). LFA-1 antibodies have been shown to be comito- 
genic (37).  Proliferation assays were used to test T  cell re- 
sponses  in  MLR.  Responder  lymph  node  cells  from 
CDlla -/-  mice (H-2  b) showed reduced proliferative re- 
sponses  to  BALB/c  (H-2d),  B10  BR  (H-2k),  and  BM12 
(H-2  bm12) stimulator cells  (Fig.  5  B).  In vitro lymphocyte 
proliferative responses to soluble anti-TCtk-CD3 antibod- 
ies were only 10% compared to controls (Fig.  5 D). These 
results  confirm  LFA-1  involvement  in  T  cell  activation 
(38).  Surprisingly, if CD1 la-/-  lymphocytes were cross- 
linked with anti-CD3  antibody fixed to plastic wells, pro- 
hferative responses were normal  (Fig.  5  C), although blast 
cell  formation  was  delayed  by  several  hours  (data  not 
shown). 
CD11a  --/-  Mice Have  Reduced  Thioglycollate-induced 
Peritonitis.  Peritoneal lavage ofthioglycollate-induced peri- 
tonitis showed a reduction in the total number of infiltrating 
leukocytes derived from  -/-  mutant  mice.  Neutrophils 
and monocytes exhibit different time courses for extravasa- 
tion in response to inflammatory stimuli. Accordingly, neu- 
trophil infiltration at 4 h and monocyte infiltration at 24 h 
was reduced compared to heterozygous controls (Fig. 6). 
CD11a  -/-  CD8+  T  Cells Show Normal  CTL Effector 
Function.  Since LFA-1 was initially reported as a molecule 
centrally involved in CTL and NK cell killer function (1, 2, 
18,  39,  40),  we  naturally  investigated  CTL  function  in 
CDlla  -/-  mutant mice. Mice were injected i.v. with 
2  ￿  103 PFU LCMV at day -8  or 2  ￿  106 PFU VSV at 
day  -6.  Spleens  from infected mice  were  removed and 
splenocytes  incubated  with  51Cr-labeled  target  cells  in- 
fected with  VSV  or  loaded  with  LCMV  peptide  (1033). 
Contrary to expectations from results of previous reports, 
splenocytes from CDlla  -/-  mice were found to mount 
normal in vivo CTL responses to both VSV (Fig. 7, A and B) 
and LCMV (Fig. 7 D). CTL from VSV-infected mutant mice 
lysed both ICAM-l-positive (EL-4) (Fig. 7 A) and ICAM-1- 
negative (MC57) VSV-infected targets (Fig. 7 B) (30). 
Ex vivo CTL function was also  determined using mac- 
rophage  target  cells  derived  from  thioglycollate-injected 
CDlla  -/-  mutant mice. This was intended to assess if 
compensatory changes in CTL from -/-  mice might have 
masked an obvious defect in CTL responses in vivo. We 
found no significant difference for CTL-mediated lysis us- +/§  +I- 
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Figure 3.  (a) Peripheral  blood cells were 
stained with PE-conjugated  anti-CD18 and 
FITC-conjugated anti-B220  or FITC-con- 
jugated anti-CD3  (top two panels). (b) PBL 
were  stained  with  PE-conjugated  anti- 
CD1 la and FITC-conjugated  anti-CD 1  ~  b. 
Loss of CD11a expression results in reduc- 
tion  in  CDI8  surface expression  level, 
which  corresponds  to  expression  levels  of 
CD1 lb  on  lymphocytes.  FACS  |  data  was 
collected  for viable lymphocytes  according 
to SSC and FSC. 
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ing +/-  or -/-  cytotoxic effector cells against  -/-  tar- 
gets (Fig. 7, E  and F). 
Secondary Restimulation  Against  VSV Is Normal in  CD1 la 
-/-  Mice.  Splenocytes  from  mice  irmnunized  with  VSV 
(2  ￿  106  PFU)  were  restimulated  with VSV  nuclear  pro- 
tein class-l-binding peptide in culture for 5  d. Specific cy- 
totoxicity  against  VSV-infected  EL-4  (H-2  b)  target  cells 
was  comparable  with  wild-type  control  mice  (Fig.  7  C). 
Specific lysis of non-infected EL-4 cells was below 10% for 
all  effector cells.  Spontaneous  release  was  below  20%  for 
both  targets. 
NK Cytotoxidty Is Markedly Reduced.  NK cells from C D 11 a 
-/-  mice  were  defective  in  their  ability  to  kill  YAC-1 
targets  (Fig.  8),  and  this  inhibition  was  comparable  to  re- 
duced  killing  observed  after  treatment  with  anti-CDlla 
mAb  (41,  42). 
Delayed-type  Hypersensitivity  Is  Absent  in  CDlla  -~- 
Mice.  Anti-LFA-1  mAb  treatment  during  either priming 
Figure 4.  Normal T cell subsets in Thymus and Lymph nodes, Leuko- 
cytes from  +/+,  +/-,  and  -/-  CD11a  mice.  Thymocytes,  lymph 
node cells, and peripheral blood leukocytes were stained with PE-conju- 
gated  anti-CD8 and  FITC-conjugated anti-CD4.  No detectable  difi?r- 
ence was seen in T  cell subsets from these organs. FACS  |  data was col- 
lected for viable lyrnphocytes according to SSC and FSC, 
1420  Normal Viral Responses but No Tumor Rejection in LFA-l-deficient Mice or rechallenge has been reported to block delayed-type hy- 
persensitivity  (DTH)  inflammatory  responses  in  mice  (16, 
17).  The  DTH  responses requires T  cell priming in drain- 
ing lymph  nodes and recirculation  of T  cells to  skin.  6-8- 
wk-old  mice  were  immunized  twice  with  DNFB  and re- 
challenged  after  5  d  on  one  ear.  After  24  h  ear  thickness 
was  measured  and  compared  with  the  untreated  ear.  Her- 
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Figure  5.  Lymphocyte  func- 
tion in mutant mice. (A) Homo- 
typic  aggregation of splenocytes 
from +/-,  and -/-  mice stim- 
ulated  with  phorbol  myristate 
acetate  (PMA  100  ng/ml  for 
24h).  (B)  MLR's  were  per- 
formed by mixing 1 ￿  10  s  irra- 
diated spleen cells from C57BL/6, 
BALB/c,  B10.BR,  or  bml2 
mice with  1 X  10  s lymph node 
cells harvested from +/-  (cross- 
hatched  bars)  or  -/-  (open  bars) 
mice.  Each bar represents  indi- 
vidual mice.  (Results  are  shown 
for  the  5-d  time  point;  similar 
results  were  obtained  at  3  and 
4 d. Similar results were obtained 
in  three  independent  experi- 
ments).  (C)  Proliferation  assay. 
Lymph  node  cell  suspensions 
were prepared from  +/+  (black 
bars),  +/-  (cross-hatched  bars), 
and -/-  (open  bars) and stimu- 
lated.  For  stimulation  by  anti- 
body cross-hnking, lymph node 
cells were  placed  in  plates  pre- 
coated  with  rabbit anti-hamster 
IgG  and  hamster  anti-murine 
CD3 MAb (10 p~g/ml). (D) Pro- 
liferative  responses  to  soluble 
anti-CD3.  10  s lymph node cells 
were  plated  into  each well  and 
purified  hamster  anti-murine 
CD3  added  (10  p,g/ml).  Be- 
tween 24 and 72 h, proliferating 
cells were  pulsed with  [3H]thy- 
midine  and  cultured  overnight. 
Data  represent  averages  of 
quadruplicates.  (Closed  triangles 
+/+;  dosed  squares  +/-;  open 
triangles  -  / -  .) 
erozygous  littermates  showed  expected  visible  swelling  of 
the  treated  ear while  DTH  was  virtually absent in CD11a 
-/-  mice  (Fig.  9). 
CD11a  -/-  Mice  Do  Not  Prime~Reject  Injected  Tumor 
Cells.  We tested the ability of mutant mice to reject a trans- 
plant with immunogenic  fibrosarcoma tumor  cells (MC57, 
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Figure  6.  Leucocyte  migra- 
tion  in  response  to  intraperito- 
neal  injection  of thioglycollate. 
Total  leucocyte  (A), polymor- 
phonuclear  leucocyte  (B)  and 
monocyte (C) numbers were as- 
sessed  at  the  indicated  time 
points after i.p.  injection of 1.5 
ml of 4% thioglycollate  in +/- 
and  -/-  mutant  mice.  Data 
shown as  mean  +/-  SEM  for 
groups  of  five  age-  and  sex- 
matched animals per time point. 
Sohd  circles  are  +/-  mice; 
open  circles  are  -/-  mutant 
mice. 
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Figure 7.  CTL responses are normal in CD1 la -/-  mice. Normal VSV-specific CTL responses. (A and B) CDlla  +/+  (closed triangles) and CD1 la 
-/-  (open triangles) mice were infected intravenously with VSV (2  ￿  106 PFU). VSV-infected syngeneic targets were either ICAM-l-positive (A) (EL- 
4) or ICAM-l-negative (B) (MC57). Closed circles represent non-infected control CD1 la +/+  mice. Specific lysis of non-infected control targets <5%; 
spontaneous lysis of all targets <25%.  (C) Secondary restimulation against VSV is normal in CD 1 la-/-  mice. Splenocytes from mice immunized with 
VSV (2  ￿  106 PFU) were restimulated with VSV nuclear protein class-l-binding peptide in culture for 5 d. Specific cytotoxicity against VSV-infected 
EL-4 (H-2  b) target cells was comparable with wild-type control mice. Specific lysis of non-infected EL-4 cells was below 10% for all effector cells. Spon- 
taneous release was below 20% for both targets. (D) Normal LCMV-specific CTL responses. Mice were injected i.v. with 2  ￿  103 PFU. LCMV at day 
-8  or 2  ￿  106 PFU. VSV at day -6. Splenocytes from infected mice were incubated with SlCr-labeled target loaded with LCMV-GP peptide. CDlla 
-/-  mice were found to mount normal in vivo CTL responses. (E) Normal ex vivo CTL response to  -/-  targets. Mice were injected with 2  ￿  103 
PFU LCMV at day -8. Macrophages were obtained from -/-  mutant mice injected with 1nil thioglycollate at day -5, harvested by peritoneal lavage 
at day -1  and labeled overnight with LCMV-gp peptide. Targets were incubated with SlCr for 2 h before assay. Splenocytes from infected mice were in- 
cubated with labeled target cells for 5 h. Open triangles represent -/-  effectors; closed triangles represent +/-  effectors. (Spontaneous release was be- 
low 15'% for all assays and +SD was less than 5% for for each data point.) 
footpads induces lymphocytic infiltration of footpads and a 
visible  swelling  reaction  by  6-9  d,  followed  by  tumor 
clearance  and  normalization  of footpad  thickness  within 
14 d.  CDlla  mutant mice showed  no  swelling at 6-9  d, 
and developed massive tumor burdens by day 14 (Fig.  10). 











and mutant mouse footpads confirmed the presence of ma- 
lignant cells and the absence ofleukocytes (Fig.  10,  D  and 
E). We then immunized mice into footpads with the fibro- 
sarcoma cell  line  MC57-gp  (the  same MC57  cell line  as 
above  transfected  to  express  the  major  immunogenic 
epitope of the LCMV glycoprotein [30])  to induce  CD8 + 
CTL responses against LCMV in H-2  b mice (43).  7 d after 
injection of live MC57-gp into  footpads, LCMV-gp-spe- 
cific CD8 + CTL became detectable in spleens of CD11a +/- 
mice but not in CDlla -/- mice (Fig.  10 F). Accordingly, 
CD11a +/-  mice,  but  not  CD11a -/-  mice,  cleared  the 
MC57-gp tumor cells (data not shown). 
Discussion 
The role of adhesion molecules during the  cellular im- 




Figure  8.  Natural killer cells are defective in CDlla  -/-  mice. The  ~  @- 
NK  sensitive cell line YAC-1  was SlCr-labeled  and used as  targets for 
spleen mononuclear (NK)  cells.  Percent specific lysis is  represented for  ~  30- 
+/+  (solid  triangles),  +/-  (solid squares),  and  -/-  mice (open  triangles).  ~  !0- 
Data represents mean +/-  SEM  specific lysis for 7  mice of each type 
analysed in three independent experiments. For induction of NK activity  z0- 
in vivo, mice were injected into peritoneum with 100 [~g poly(I):poly(C)  0 
on days 0 and 1 and analyzed on day 2.  +)- 
Figure 9.  Absence of DTH re- 
sponse  in  CDlla  -/-  mice. 
Four  +/-  (crosshatched bar) and 
four  -/-  (open  bar) mice were 
immunized on shaved abdomen 
and rechallenged on one ear with 
DNFB. Ear thickness is shown as 
a  percentage  of swelling  com- 
pared to the untreated ear. 
1422  Normal Viral Responses but No Tumor Rejection in LFA-l-deficient Mice Figure  10.  Defective tumor 
surveillance in mutant mice. (A) 
2  >(  10  s  MC57  fibrosarcoma 
cells  (C57BL/6  derived)  were 
injected  subcutaneously  into 
one  footpad of  CD11a  -/- 
mice  (open symbols) and CD11a 
+/-  mice (closed  symbols). Foot- 
pad swelling  was monitored daffy 
ruing  a  spring loaded caliper. 
Different markers represent re- 
suits from three independent ex- 
periments, each using 2--4 mice 
for a  total of 10  -/-  mutant 
mice  and  10  +/-  littermate 
controls. (B and C') Histology on 
footpad  from  +/-  mouse on 
day 15. Lymphocytes are visible 
as small dark-stained cells. Circle 
shows  a  high  concentration of 
infiltrating lymphocytes. (D and 
E)  Histology on  footpad from 
-/-  mouse on day 15 showing 
tumor  cells. Insert demonstrates 
mitotic tumor cells (indicated by 
arrows).  (F)  Day  7  splenocytes 
from  animals  injected  with 
MC57-GP  (MC57 cell line sta- 
bly expressing with LCMV gly- 
coprotein) into  footpad are  re- 
stimulated in vitro with peptide 
for 5 d and assayed for CTL ac- 
tivity using peptide-loaded EL-4 
target cells in a SlCr release assay. 
Magnification: B and /9,  150>(; 
C and F, 750>(; F, inset, 2250>(. 
ciated  with  recirculation  through  the lymphatic network, 
interaction  with  and migration  through  endothelial  lining 
of blood vessels, cellular adhesion events important during 
antigen specific activation,  and, finally,  cell contact during 
T  ceil  effector functions  (reviewed by Springer et al.  [9]). 
In vitro and in vivo findings suggest that LFA-1 is impor- 
tant in lymphocyte migration across the HEV into periph- 
eral  LN  and  Peyer's patches  (22).  Thus  it  would  be  ex- 
pected that immune reponses to peripheral antigens, where 
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priming of T  cell responses  occurrs in the  draining lymph 
nodes,  would  be  defective  in  LFA-l-deficient  mice.  We 
used intravenous infection to assess CTL responses in mu- 
tant  mice.  Because  i.v.  infection  results  in  a  viremia  and 
dissemination  of  virions  lymphocytes  are  likley  to  be 
primed in the spleen,  circumventing the need for efficient 
lymphocyte recirculation through lymph nodes and migra- 
tion across endothelial barriers. 
Nevertheless,  in contrast to reports that LFA-1 is crucial for lymphocyte proliferation against virus-infected cells and 
CTL  effector  function  (1,  18,  19),  ex  vivo  assays  from 
LCMV- and VSV-infected CD11a  -/-  mutant mice re- 
vealed that LFA-1  deficient CTL had no defect in killing 
cell  line-derived  targets.  These  assays  also  suggested  that 
antigen-specific  CTL  had  undergone  sufficient  prolifera- 
tion in vivo for normal killing responses ex vivo. The im- 
plication  of these  observations  is  that  LFA-1--deficient T 
cells are capable of undergoing activation and proliferation 
with no discernable defect compared to normal mice. Re- 
ports  that  lymphocyte proliferation  and  CTL function  is 
defective after anti-LFA-1  antibody treatment might be a 
characteristic  of the in vitro nature  of the assay,  or might 
reflect  non-specific  effects of antibody treatment,  such  as 
capping of other crucial surface molecules or even killing of 
effector cells.  On  the  other  hand,  T  cells  developing in 
LFA-l-deficient mice may have compensatory alterations 
in the expression of other molecules that may serve to mask 
the  LFA-1  defect.  Ex vivo CTL function  using  +/-  or 
-/-  CTL against targets derived from CD11a -/-  mice 
suggested that CD 1 l a -/-  effectors were no better at kill- 
ing -/-  targets than were effector cells that had developed 
in mice with normal levels ofLFA-1. IfT cell development 
in  CD11a  -/-  mice  had  managed  to  compensate  for 
LFA-1 deficiency, as evidenced by normal response in vivo to 
virus, it was not evident in a differential ability to kill -/- 
targets in vitro. If anything,  +/-  effectors appeared to be 
slightly better at killing -/-  targets in this sensitive assay, 
which may reflect a slight outpefformance (proliferation and 
or killer function)  ofT cells from LFA-l-expressing mice. 
It should be mentioned that mutant mice also have about 
twofold greater number of splenocytes than heterozygous 
mice, thus any minor defect in CTL responses to virus in 
mutants  may be overcome by the sheer excess of T  cells 
present. 
Peritoneal lavage after thioglycollate treatment indicated 
that LFA-1 is not crucial but nevertheless important in ex- 
travasation  of polymorphonuclear leukocytes  and  mono- 
cytes  into  the  peritoneum  in  response  to  inflammatory 
stimulus. Observed decreases in infiltrate reflected an abso- 
lute reduction in cell numbers rather than a shift in the ki- 
netics of the inflammatory response. This finding suggests a 
significant role for LFA-1 in neutrophil and monocyte re- 
sponses to local infection. 
DTH responses against DNFB  were virtually absent in 
LFA-l-deficient mice. Moreover, immunization in the base 
of the taft with KLH or OVA in CFA or incomplete FA 
had little  affect on the  size  of inguinal  or paraortic LNs, 
whereas similar treatment on heterozygons mice resulted in 
marked lymphoadenopathy (data not shown). Both of these 
situations could be explained by a recirculation defect, but 
do not rule out a defect in priming. The lack of tumor re- 
jection  aider inoculation  of MC57  fibrosarcoma cells  into 
footpads  and  the  failure  of LCMVgp-transfected  MC57 
cells to prime ag-specific responses are also consistent with 
a recirculation defect in CD1 la -/-  mice. 
Although this is the first report that LFA-1 is crucial for 
priming immune responses against non-virus-induced syn- 
geneic tumors, these results again do not determine if a de- 
fect in priming in  draining  peripheral LN  accompanies a 
lymphocyte recirculation defect. However, our studies with 
LCMV and VSV infections suggests that priming is effcient 
in the absence of LFA-1, at least, as it appears, in the con- 
text of virus infections in the  spleen. Differential priming 
requirements could reflect the involvement of different types 
of APC  in  the  peripheral lymph nodes  versus the  spleen 
(24).  The importance of the strength of the activation sig- 
nal in LFA-l-deficient cells  is exemplified by our finding 
that  proliferative  responses  of CD11a-/-  lymphocytes 
was absent aRer treatment with soluble CD3 but relatively 
normal after treatment with  cross-linked anti-CD3  mAb. 
Our  in  vitro  findings  that  proliferation  of CDlla  -/- 
lymphocytes is significantly reduced contrasts with in vivo 
responses of CD1 la -/-  mice to systemic virus infections. 
Taken together,  our results suggest a  differential require- 
ment for LFA-1  for lymphocyte activation and prolifera- 
tion depending,  perhaps, on the type of APC involved in 
presenting antigen to T  cells, or, on the microenvironment 
in which antigen presentation occurs. 
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